Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Lilly Does Not Expect A Quick Medicare Coverage Decision For Donanemab
Eisai Will Make A Case For Lecanemab Soon
Dec 15 2022
•
By
Mandy Jackson
Gaining Medicare reimbursement will take time even with Phase III data in hand • Source: Shutterstock
More from Drug Pricing
More from Scrip